On the types of assessments concerning the effectiveness of medical procedures
Abstrakt
PEŁNY TEKST:
PDFReferences
1. Miller F.G., Brody H., Chung K.C., Cosmetic surgery and the internal morality of medicine, “Cambridge Quarterly of Healthcare Ethics” 2000; 9: 353–364.
2. Tragakes E., Vienonen M., Key Issues in Rationing and Priority Setting for Health Care Services, WHO/EURO Health Services Management, New York 1998.
3. Gilbert R.E., Augood C., Gupta R., Ades A.E., Logan S., Sculpher M., van Der Meulen J.H., Screening for Down’s syndrome: effects, safety, and cost effectiveness of first and second trimester strategies, “British Medical Journal” 2001; 323: 1–6.
4. Park R.E., Fink A., Brook R.H., Physician ratings of appropriate indicators for six medical and surgical procedures, “Am. J. Public Health” 1986; 76: 766–772.
5. Mandelblatt J.S., Fryback D.G., Weinstein M.C., Assessing the effectiveness of health interventions for cost-effectiveness analysis, “Journal of General Internal Medicine” 1997; 12 (9): 551–558. doi:10.1046/j.1525-1497.1997.07107.x.
6. Haynes B., Can it work? Does it work? Is it worth it? The testing of healthcare interventions is evolving, “British Medical Journal” 1999; 319: 652–653.
7. Marley J., Efficacy, effectiveness, efficiency, “Australian Prescriber” 2000; 23: 114–151.
8. Luce B.R., Drummond M., Jönsson B., Neumann P.J., Schwartz J.S., Siebert U., S.D., EBM, HTA, and CER: Clearing the Confusion, “Milbank Q” 2010; 88 (2): 256–276. doi: 10.1111/j.1468-0009.2010.00598.x
9. Rynek Zdrowia, 19 listopada 2015 r., Eksperci: leki w iniekcjach to mniejsze koszty leczenia schizofrenii; http://www.rynekzdrowia.pl/Uslugi-medyczne/Eksperci-leki-w-iniekcje-to-mniejsze-kleszty-leczenia-schizofrenii,156900,8.html (accessed: 01.10.2017).
10. NICE (The National Institute for Health and Care Excellence), Guide to the methods of technology appraisal 2013; https://www.nice.org.uk/process/pmg9/chapter/foreword, (accessed: 01.10.2017).
11. AOTMiT (Agencja Oceny Technologii Medycznych i Taryfikacji), Wytyczne oceny technologii medycznych (HTA), AOTMiT, Warszawa 2016.
12. Muldoon M.F., Manuck S.B., Matthews K.A., Lowering cholesterol concentrations and mortality: A quantitative review of primary prevention trials, “British Medical Journal” 1990; 301 (6747): 309–314.
13. Fleming T.R., DeMets D.L., Surrogate end points in clinical trials: Are we being misled? “Ann. Mem. Med.” 1996; 125: 605–613.
14. Ross W.D., Foundations of Ethics. The Gifford Lectures, Oxford University Press, Oxford 2000.
15. Howard K.I., Mora K., Brill P.L., Martinovich, Z., Lutz W., Evaluation of psychotherapy: Efficacy, effectiveness, and patient progress, “American Psychologist” 1996; 51: 1059–1064.
16. Sassi F., Le Grand J., Archard L., Equity versus efficiency: a dilemma for the NHS : If the NHS is serious about equity it must offer guidance when principles conflict, “British Medical Journal” 2001; 323 (7316): 762–763.